– A critical oncology drug, Linperisib (因他瑞), has been out of stock for months, forcing patients to pay over 10,000 RMB per bottle through unofficial channels with no guarantee of supply.
– Yingli Pharma (上海璎黎药业有限公司), the drug’s developer, is facing severe operational and financial distress, including office closures, legal disputes, and supply chain failures.
– The Linperisib supply crisis was exacerbated by its removal from the National Reimbursement Drug List (NRDL, 国家医保药品目录) and a failed supplemental indication approval, crippling its commercial viability.
– Strategic investor and commercialization partner恒瑞医药 (Jiangsu Hengrui Pharmaceuticals Co., Ltd.) has not committed to resolving the shortage, leaving the drug’s future and patient access in limbo.
– This incident highlights systemic risks in China’s biotech sector, including over-reliance on single products, fragile financing, and the urgent need for resilient supply chains.
The Deepening Linperisib Supply Crisis: A Patient Nightmare Unfolds
For hundreds of patients battling relapsed or refractory lymphomas in China, the past several months have been marked by desperation and fear. A severe and prolonged shortage of Linperisib (林普利塞), a targeted PI3Kδ inhibitor branded as Yintarui (因他瑞), has left individuals and their families scrambling to find this life-extending therapy, often at exorbitant out-of-pocket costs. The Linperisib supply crisis is not merely a logistical failure; it is a stark illustration of the fragility within China’s ambitious biopharmaceutical ecosystem when commercialization strategies falter and corporate distress directly impacts public health.
Reports from patients and caregivers confirm that the drug vanished from hospital pharmacies and retail channels across the country beginning in the fourth quarter of 2025. With the medication priced at 11,040 RMB per bottle—a month’s supply for many—the financial burden is crushing. Even those willing to pay this sum are frequently unable to locate any stock, turning to unverified online pleas and underground networks. This breakdown in access underscores a critical failure in the patient assistance programs and supply chain management promised by the manufacturer, Yingli Pharma (上海璎黎药业有限公司).
Voices from the Frontlines: Patients Abandoned by the System
The human cost of this Linperisib supply crisis is immense. Take the case of Yang Yang (a pseudonym), a family member caring for a patient with peripheral T-cell lymphoma. After other treatments failed, Linperisib provided a crucial lifeline starting in 2024. However, by September 2025, their supply dried up. Compounding the hardship, Yingli Pharma’s patient assistance program, which promised “buy six, get three free” bottles, left them with one promised bottle never delivered—a broken commitment that adds financial insult to medical injury.
On Chinese social media platforms, distress signals are visible. Posts from users in Beijing, Shanghai, and beyond plead for information on where to find remaining stock, with one user stating plainly, “My father has nothing to eat, seeking leftovers.” This scenario forces patients to consider switching to alternative, often less suitable or vastly more expensive therapies, such as Golidixitinib (戈利昔替尼), which before医保 coverage cost over 30,000 RMB per month. The Linperisib shortage has, therefore, created a dangerous vacuum in treatment protocols for a vulnerable patient population.
Yingli Pharma’s Downfall: From Biotech Star to Operational Collapse
The源头 of this supply disaster traces back to the escalating troubles at Yingli Pharma. Once hailed as a rising star for its innovative drug development and a strategic 2000 million USD investment from恒瑞医药, the company is now emblematic of the sector’s volatility. Visits to its registered office in Shanghai’s漕河泾康桥商务绿洲 (Caohejing Kangqiao Business Oasis) in early February revealed a scene of disintegration: doors sealed with cross-over white strips, emptied laboratories, and workers packing equipment for a move.
Company employees on-site, speaking under condition of anonymity, confirmed a relocation driven by a dispute with the landlord over rents cited at 3.6 RMB per square meter per month. They stated the workforce had dwindled to around 30 people and admitted to outstanding debts to suppliers being paid in installments. Despite Yingli Pharma’s official声明 (statement) on February 11 insisting all operations were normal, the physical evidence and employee accounts painted a picture of a company in severe distress, struggling to maintain basic functions.
Financial and Legal Quagmire: Lawsuits and Mounting Debts
Public records from天眼查 (Tianyancha) reveal the depth of Yingli Pharma’s financial woes. Since 2025, the company has been named as a defendant in over 30 lawsuits, including disputes over supply contracts, service agreements, and patent agency fees. In a telling case, a judgment from the Shanghai Pudong New Area People’s Court in October 2025 ordered Yingli Pharma to pay 2.2514 million RMB in service fees and penalties to contract research organization康龙化成 (Pharmaron). As a result, the company was listed as a被执行人 (enforcement subject), and its legal representative, HUI MICHAEL XIN (惠欣), was subjected to consumption restrictions.
These legal entanglements directly impact the Linperisib supply chain. The drug’s production is outsourced to江苏宣泰药业有限公司 (Jiangsu XuanTai Pharmaceutical Co., Ltd.), as listed on the National Medical Products Administration (NMPA, 国家药品监督管理局) website. With Yingli Pharma unable to pay its partners reliably, the continuity of manufacturing and distribution is thrown into jeopardy, creating the perfect storm for the ongoing Linperisib supply crisis.
Regulatory and Market Setbacks: The Perfect Storm for Linperisib
The commercial foundations for Linperisib were already cracking before the supply vanished. Approved in November 2022 for follicular lymphoma, its journey to blockbuster status hit two major roadblocks. First, in June 2024, the NMPA did not approve its supplemental New Drug Application (NDA) for peripheral T-cell lymphoma (PTCL)—a key indication that would have significantly expanded its patient base and revenue potential. The company, with its partner恒瑞医药, voluntarily withdrew the application for further study, but no resubmission timeline has been provided.
Second, and arguably more devastating, was its expulsion from the National Reimbursement Drug List (NRDL). After being included in the 2023 NRDL with coverage from 2024-2025, Linperisib failed to secure renewal in the 2025 negotiations and was formally delisted. This loss of医保报销 (medical insurance reimbursement) instantly made the drug unaffordable for the vast majority of Chinese patients, destroying its market accessibility and commercial appeal for恒瑞医药 as the commercialization partner. The Linperisib supply crisis is thus both a cause and a consequence of its plummeting commercial viability.
The Pipeline Problem: Over-Reliance on a Single Asset
A core vulnerability exposed by this事件 (incident) is Yingli Pharma’s thin product pipeline. Beyond Linperisib, the company has only one other asset, YL-90148 for hyperuricemia/gout, in Phase IIIa trials. All other candidates are in preclinical or early clinical stages. This over-dependence on a single commercial product is a common pitfall for emerging biotechs. When that product faces clinical, regulatory, or market headwinds, the entire company’s survival is at stake. The Linperisib supply crisis, therefore, serves as a cautionary tale for investors assessing Chinese biotech firms: robust pipelines and diversified risk are non-negotiable for long-term sustainability.恒瑞医药’s Dilemma: Assessing a Troubled Partnership
All eyes are now on恒瑞医药, China’s pharmaceutical giant, which holds the exclusive commercialization rights for Linperisib in Greater China following its 2000 million USD investment. The company’s response to the escalating Linperisib supply crisis will be a bellwether for its partnership strategy and corporate governance. In a statement to the media,恒瑞医药 said it “has been actively assisting in related matters within the cooperation framework” and that “follow-up cooperation arrangements are still under communication.”This carefully worded non-commitment leaves significant uncertainty.恒瑞医药 must weigh the cost of rescuing the supply chain and potentially re-investing in a drug with compromised market access against the reputational damage of abandoning patients and a partner. For institutional investors tracking恒瑞医药’s external innovation strategy, this situation presents a critical case study in risk management and partnership due diligence.
Strategic Implications for M&A and Collaboration in Chinese Pharma
The unfolding drama between Yingli Pharma and恒瑞医药 highlights the complexities of strategic alliances in China’s fast-moving drug development sector. Large pharma companies like恒瑞医药 seek to bolster their pipelines by investing in or acquiring innovative biotechs. However, as seen here, these bets can sour quickly if the asset encounters problems or the biotech’s operational fundamentals weaken. The Linperisib supply crisis may make恒瑞医药 and other large players more cautious, potentially leading to more stringent covenants, staged payments, or outright acquisitions rather than minority stakes in future deals.Broader Lessons for China’s Biotech and Healthcare Investment Landscape
The Linperisib saga transcends a single company’s failure. It exposes interconnected vulnerabilities in the system: from drug pricing and医保 negotiation dynamics to supply chain resilience and corporate governance in capital-intensive biotech. For global investors and fund managers focused on Chinese healthcare equities, this incident underscores the need to look beyond scientific innovation and assess commercial execution, financial health, and contingency planning.Policy Considerations and the Path Forward
Regulatory bodies like the NMPA and the National Healthcare Security Administration (NHSA, 国家医疗保障局) may face pressure to develop mechanisms to prevent such critical drug shortages. This could involve enhanced monitoring of marketing authorization holders’ financial health, requirements for backup manufacturing plans, or special provisions for lifesaving drugs during corporate distress. The Linperisib supply crisis is a test case for whether China’s regulatory framework can evolve to protect patient access without stifling innovation.For patients currently enduring the Linperisib supply crisis, the immediate need is for a coordinated intervention by恒瑞医药, Yingli Pharma, and health authorities to restart production and distribution, potentially through emergency measures or technology transfer. In the longer term, this episode should catalyze a broader industry and policy discussion on building a more robust and patient-centric biopharmaceutical ecosystem in China—one where scientific promise is matched by reliable delivery to those in need. Investors must now scrutinize portfolio companies for similar single-asset risks and fragile supply chains, while advocating for greater transparency and accountability from all stakeholders in the healthcare value chain.